Sartorius | SRT3 - Selling And Administration Expenses


Sartorius reported EUR216.6M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 447K 138K Mar/2026
Avita Medical AUD 19.03M 1.95M Dec/2025
Dianthus Therapeutics USD 12.47M 5.89M Mar/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
IQVIA Holdings USD 574M 72M Jun/2026
Moderna USD 216M 43M Jun/2026
Organon & Co USD 434M 10M Jun/2026
Revvity USD 278.58M 24.69M Jun/2026
Sartorius EUR 216.6M 4.7M Sep/2026
Tectonic Therapeutic USD 6.43M 2.99M Mar/2026
Viatris USD 1.13B 205.7M Jun/2026
Xeris Pharmaceuticals USD 53.14M 10.51M Mar/2026